Related references
Note: Only part of the references are listed.Oncological Outcomes Following Omission of Axillary Lymph Node Dissection in Node Positive Patients Downstaging To Node Negative with Neoadjuvant Chemotherapy: the OPBC-04/EUBREAST-06/OMA study
Giacomo Montagna et al.
CANCER RESEARCH (2023)
Axillary surgery in node-positive breast cancer
Nadia Maggi et al.
BREAST (2022)
Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol
Ariane A. van Loevezijn et al.
BREAST CANCER RESEARCH AND TREATMENT (2022)
Patient-reported outcomes (PROs) for the intergroup sentinel mamma study (INSEMA, GBG75, ABCSG43): Persistent impact of axillary surgery on arm and breast symptoms in early breast cancer
Bernd Gerber et al.
CANCER RESEARCH (2022)
Breast Cancer, Version 3.2022
William J. Gradishar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)
Clinical feasibility and oncological safety of targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: A prospective registry study
S. Wu et al.
ANNALS OF ONCOLOGY (2022)
AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022
Maggie Banys-Paluchowski et al.
GEBURTSHILFE UND FRAUENHEILKUNDE (2022)
Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer
Janine M. Simons et al.
JAMA SURGERY (2022)
A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients
Sherko Kuemmel et al.
ANNALS OF SURGERY (2022)
Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up
Sabrina Kahler-Ribeiro-Fontana et al.
EJSO (2021)
Feasibility and reliability of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients with positive axillary nodes at initial diagnosis: An up-to-date meta-analysis of 3,578 patients
Siyang Cao et al.
BREAST (2021)
AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update
Michael Friedrich et al.
GEBURTSHILFE UND FRAUENHEILKUNDE (2021)
The Evolving Role of Marked Lymph Node Biopsy (MLNB) and Targeted Axillary Dissection (TAD) after Neoadjuvant Chemotherapy (NACT) for Node-Positive Breast Cancer: Systematic Review and Pooled Analysis
Parinita K. Swarnkar et al.
CANCERS (2021)
Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study
Maggie Banys-Paluchowski et al.
CANCERS (2021)
The applicability of Magseed? for targeted axillary dissection in breast cancer patients treated with neoadjuvant chemotherapy
R. Reitsamer et al.
BREAST (2021)
Axillary management in T1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy (ATNEC).
Amit Goyal et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Andrew N. J. Tutt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Options to Determine Pathological Response of Axillary Lymph Node Metastasis after Neoadjuvant Chemotherapy in Advanced Breast Cancer
Vijayashree Murthy et al.
CANCERS (2021)
Carbon tattooing for targeted lymph node biopsy after primary systemic therapy in breast cancer: prospective multicentre TATTOO trial
S. Hartmann et al.
BRITISH JOURNAL OF SURGERY (2021)
Targeted axillary dissection-standard or still experimental?
Marc Thill et al.
GYNAKOLOGE (2021)
Patterns of axillary staging and management in clinically node positive breast cancer patients treated with neoadjuvant systemic therapy: Results of a survey amongst breast cancer specialists
J. M. Simons et al.
EJSO (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
De-escalation of Axillary Surgery in the Neoadjuvant Chemotherapy (NACT) Setting for Breast Cancer: Is it Oncologically Safe?
Umar Wazir et al.
ANTICANCER RESEARCH (2020)
A Review of Options for Localization of Axillary Lymph Nodes in the Treatment of Invasive Breast Cancer
Ryan W. Woods et al.
ACADEMIC RADIOLOGY (2019)
Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement
Ramon Colomer et al.
ONCOLOGIST (2019)
Validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Preliminary results
Diego Flores-Funes et al.
SURGICAL ONCOLOGY-OXFORD (2019)
Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation
Giacomo Pelizzari et al.
CANCER TREATMENT REVIEWS (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019
Nina Ditsch et al.
BREAST CARE (2019)
Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+Subtypes
Brittany L. Murphy et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2018
Cornelia Liedtke et al.
BREAST CARE (2018)
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
Sara A. Hurvitz et al.
LANCET ONCOLOGY (2018)
Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy
Alison U. Barron et al.
JAMA SURGERY (2018)
Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial
Guido Henke et al.
TRIALS (2018)
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial
S. Loibl et al.
ANNALS OF ONCOLOGY (2017)
Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery
Audree B. Tadros et al.
JAMA SURGERY (2017)
Axillary Nodal Management Following Neoadjuvant Chemotherapy A Review
Melissa Pilewskie et al.
JAMA ONCOLOGY (2017)
Combined PET-CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node-positive breast cancer after neoadjuvant therapy
B. B. Koolen et al.
BRITISH JOURNAL OF SURGERY (2017)
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2017
Cornelia Liedtke et al.
BREAST CARE (2017)
Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection
Abigail S. Caudle et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials
Raquel F. D. van la Parra et al.
BREAST CANCER RESEARCH (2016)
Marking Axillary Lymph Nodes With Radioactive Iodine Seeds for Axillary Staging After Neoadjuvant Systemic Treatment in Breast Cancer Patients The MARI Procedure
Mila Donker et al.
ANNALS OF SURGERY (2015)
Targeting and limiting surgery for patients with node-positive breast cancer
Abigail S. Caudle et al.
BMC MEDICINE (2015)
Selective Surgical Localization of Axillary Lymph Nodes Containing Metastases in Patients With Breast Cancer A Prospective Feasibility Trial
Abigail S. Caudle et al.
JAMA SURGERY (2015)
Morbidity after conventional dissection of axillary lymph nodes in breast cancer patients
Emerson Wander Silva Soares et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2014)
Morbidity Results From the NSABP B-32 Trial Comparing Sentinel Lymph Node Dissection Versus Axillary Dissection
Takamaru Ashikaga et al.
JOURNAL OF SURGICAL ONCOLOGY (2010)
Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons oncology Group trial Z0011
Anthony Lucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC trial
RE Mansel et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer
A Fleissig et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Share Paper
